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BACKGROUND: Myelosuppression has been observed with several multikinase angiogenesis inhibitors in clinical studies, although the
frequency and severity varies among the different agents. Inhibitors targeting vascular endothelial growth factor receptor (VEGFR)
often inhibit other kinases, which may contribute to their adverse-event profiles.
METHODS: Kinase selectivity of pazopanib, sorafenib, and sunitinib was evaluated in a panel of 242 kinases. Cellular potency was
measured using autophosphorylation assays. Effect on human bone marrow progenitor growth in the presence of multiple growth
factors was evaluated and correlated with the kinase selectivity.
RESULTS: Sunitinib inhibited more kinases than pazopanib and sorafenib, at potencies within 10-fold of VEGFR-2. All three compounds
potently inhibited VEGFR-2, platelet-derived growth factor receptor-b and c-Kit, However, pazopanib was less active against Flt-3 in
both kinase and cellular assays. The inhibitory properties of pazopanib, sorafenib, and sunitinib were dependent on the growth factor
used to initiate bone marrow colony formation. Addition of stem cell factor and/or Flt-3 ligand with granulocyte-macrophage colony
stimulating factor resulted in significant shifts in potency for sorafenib and sunitinib but less so for pazopanib.
CONCLUSION: Activity against c-kit and Flt-3 by multikinase angiogenesis inhibitors provide a potential explanation for the differences
in myelosuppression observed with these agents in patients.
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Kinase inhibitors often show off-target activity against additional
kinases, along with the primary intended target (Baselga, 2006;
Sebolt-Leopold and English, 2006; Karaman et al, 2008). The
activity against other kinases provides additional therapeutic
opportunities, for example, imatinib was originally developed as a
Bcr-abl kinase inhibitor; however, its inhibitory activity against
c-Kit and platelet-derived growth factor (PDGF) receptors led to its
successful clinical evaluation against gastrointestinal stromal
tumour (Buchdunger et al, 2000). However, off-target activity of
kinase inhibitors have more often been considered to be a
potential liability, which can add to the toxicities of the drug
(Liebler and Guengerich, 2005; Force et al, 2007; Campillos et al,
2008; Hasinoff et al, 2008). Knowledge of the kinase selectivity of
small-molecule kinase inhibitors can provide a better under-
standing of the biological activity and potential insights into the
mechanisms of adverse effects, thereby allowing the design of
optimally targeted multikinase inhibitors.
Myelosuppression has been observed with several vascular
endothelial growth factor receptor (VEGFR) tyrosine kinase
inhibitors (TKIs) in human clinical trials, although the frequency
and severity vary among the different agents, with sunitinib having
the highest frequency of neutropenia in 72% of patients (12%
grade 3/4), whereas pazopanib and sorafenib treatment was
associated with neutropenia in 34% (1% grade 3/4) and 18% (5%
grade 3/4) of patients, respectively. Similarly, thrombocytopenia
was observed in 65% of patients (8% grade 3/4) with sunitinib,
whereas only 32% and 12% of patients showed thrombocytopenia
with pazopanib and sorafenib (1% grade 3/4 with both agents)
(Motzer et al, 2006, 2007; Escudier et al, 2007; Bhojani et al, 2008;
Sternberg et al, 2009). Vascular endothelial growth factor and its
receptors are essential for developmental haematopoiesis, and
emerging evidence suggests a role of VEGF signalling in adult
haematopoietic stem cells (Shalaby et al, 1995; Ferrara et al, 1996;
Gerber et al, 2002; Larrivee et al, 2003). Vascular endothelial
growth factor is secreted by haematopoietic stem cells and it
inhibits total colony formation from less mature progenitor cells
and at the same time promotes the formation of myeloid, mixed,
and erythroid colonies from lineage-committed progenitors
(Gabrilovich et al, 1998; Dikov et al, 2001).
Most TKIs targeting VEGFR have been reported to inhibit other
kinases, some of which are expressed on haematopoietic
progenitor cells and have been shown to modulate their growth
and differentiation (Karaman et al, 2008). Receptors of Flt-3 and c-
Kit are two such tyrosine kinases that are expressed on early
haematopoietic progenitor cells and are involved in their
proliferation and differentiation (reviewed in Lyman and Jacobsen,
1998). The two receptors are activated by their respective ligands,
stem cell factor (SCF) for c-Kit and Flt-3 ligand for Flt-3. Further,
the haematopoietic activities of these ligands require a synergistic
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sinteraction with other early acting or lineage-selective cytokines
such as granulocyte-macrophage colony stimulating factor (GM-
CSF). The signalling through c-Kit and Flt-3 appears to be essential
for optimal production of mature haematopoietic cells from stem
cells. Flt-3 ligand is more critical for the generation of lymphoid
progenitors, whereas SCF regulates erythroid and myeloid
progenitor cells.
In this report, we investigated the effects of three VEGFR TKIs,
sunitinib (Motzer et al, 2006, 2007), sorafenib (Escudier et al,
2007), and pazopanib (Kumar et al, 2007) against a large panel of
kinases and measured their ability to inhibit VEGFR, PDGFR,
c-Kit, and Flt-3 in vitro and in cellular assays. Further, their ability
to inhibit human bone marrow progenitor growth in colony
forming assay formats induced by multiple growth factors was
tested to evaluate their potential for myelosuppression.
MATERIALS AND METHODS
Compounds
Pazopanib, sunitinib, and sorafenib were synthesized at
GlaxoSmithKline and dissolved in DMSO for treatment of cells.
Kinase selectivity screen
All three kinase inhibitors were tested against 242 kinases at 0.3mM
and 10mM concentration using KinaseProfiler (Millipore, Billerica,
MA, USA). Enzyme assays were carried out in duplicate under
optimized conditions for each enzyme. Data were represented as
percent inhibition. For IC50 values, the compounds were tested at
various concentrations ranging from 0.001 to 10mM using IC50
Profiler Express (Millipore).
Determination of in vitro potency against VEGFR-1/2/3,
PDGFR-a/b, Flt-3, and c-Kit
Human VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-b enzymes
were produced at GlaxoSmithKline. Human PDGFR-a (aa 550–
1089) was obtained from Invitrogen (Carlsbad, CA, USA). Human
Flt-3 (aa 564–end) was obtained from Millipore, and human c-Kit
(aa 544–947) was obtained from Cell Signaling Technology
(Beverly, MA, USA). For VEGFR-1/2/3, PDGFR-a/b, and Flt-3,
200–500nM enzyme was preactivated at room temperature for
45min in the presence of 0.1mM ATP. After activation, each
enzyme was diluted in assay buffer (0.2–2nM final); 30ml enzyme
mix (1.3 ) was added to 1ml (40 ) of test compound for 60min
followed by addition of 10ml( 4 ) substrate mix (ATP at Km
app for
each enzyme and 20mM peptide C, Ahx-RAHEEIYHFFFAKKK-
CONH2) in assay plates. Final assay conditions were: 100mM
HEPES (pH 7.2), 10mM MgCl2, 0.3mM DTT, 0.1mgml
 1 BSA, and
2.5% DMSO, plus
33P-ATP 0.02–0.08mCiml
 1. Assay plates were
incubated for 30min before addition of 0.5% phosphoric acid
(40ml) to stop the enzymatic reaction. Samples in plates were
mixed and 60ml transferred to a phosphocellulose filter plate for
45min before vacuum filtration and washing (4 100ml) with
0.5% phosphoric acid. Plates were dried and scintillation fluid
added before radioactive detection using a TopCount scintillation
plate reader (PerkinElmer, Waltham, MA, USA).
Activity against the c-Kit enzyme was evaluated using an HTRF
assay kit (CisBio, Bedford, MA, USA). In brief, the assay was
initiated by addition of 10ml( 2 ) c-Kit (0.5–1nM) to assay plates
containing 0.1ml (200 ) compound. Reactions were started by
addition of 10ml( 2  ) substrate mix (280mM ATP, 1mM TK
biotinylated peptide) to assay plates. Final assay conditions were:
50mM HEPES (pH 7.0), 0.1% NaN3, 5mM MgCl2,1 m M TCEP,
0.8mM CHAPS, 0.1mM orthovanadate, 0.1mgml
 1 BSA, and 0.5%
DMSO. Assay plates were then incubated for 50min at room
temperature before addition of 20ml quench buffer (containing
EDTA, strepavidin-XL665, TK antibody Eu
3þ-cryptate) to stop the
reaction and detection of phosphorylated substrate. Assay plates
were read on an EnVision multilabel plate reader (PerkinElmer)
and fluorescence was measured at 620nM (Cryptate) and 665nM
(XL665) with the ratio calculated as (665/620) for each well.
The percent maximal inhibition at VEGFR-1/2/3, PDGFR-a/b,
Flt-3, and c-Kit was plotted as a function of inhibitor concentration
to yield a concentration–response curve. Results were fit to the
IC50 equation below:
y ¼
ymax   ymin
1 þð ½ I =IC50Þ
s þ ymin
where the ymin was fixed at 0 and the ymax at 100, with IC50,
and hill slope (‘s’) parameters floating (two-parameter fit). The
Cheng–Prusoff equation (Cheng and Prusoff, 1973) was used to
convert IC50 values to Ki values. This conversion was done
assuming competitive inhibition vs ATP, as described by the
equation below:
Ki ¼
IC50
1 þð ½ S =KmÞ
All reactions were run at an ATP concentration (‘S’) for each
enzyme listed in Supplementary Table 1.
Cellular autophosphorylation assay
Ligand-induced receptor autophosphorylation assays were done to
evaluate the cellular effect of kinase inhibitors against different
receptor tyrosine kinases. For VEGFR-2 phosphorylation, human
umbilical vein endothelial cells (HUVECs) were treated with
DMSO or TKIs (ranging from 0.01 to 10mM) for 2h and then
stimulated with VEGF165 (50ngml
 1) for 10min at 371C before cell
harvesting. For c-Kit, PDGFR-b, and Flt-3 autophosphorylation,
NCI-H526, human foreskin fibroblasts, and RS4;11 cells were
stimulated with SCF (100ngml
 1), PDGF-BB (50ngml
 1), and
Flt-3 ligand (1mgml
 1), respectively. Whole-cell lysate from cells
treated with various compounds and stimulated with ligands was
prepared in radioimmunoprecipitation assay buffer containing
protease and phosphatase inhibitors. Cell lysates from NCI-H526
(200mg), HFF (200mg), HUVEC (800mg), and RS4;11 cells
(1600mg) were immunoprecipitated with 2mg of anti-c-Kit, anti-
PDGFR-b, anti-VEGFR-2, or anti-Flt-3 antibodies, respectively, by
overnight incubation at 41C. Subsequently, the antigen–antibody
complex was captured with 50ml protein A/G sepharose (Pierce,
Rockford, IL, USA) and was denatured in 0.05% b-mercaptoetha-
nol sample loading buffer, then boiled for 10min before loading
onto 8% Tris-Glycine SDS–PAGE (Invitrogen). The resolved
proteins were transferred onto PVDF membrane (Invitrogen)
and probed with 1:1000 diluted antiphosphotyrosine, anti-
VEGFR-2, anti-c-Kit, anti-PDGFR-b, or anti-Flt-3 antibodies.
Secondary, fluorescently labelled antibodies were used at
1:10000 dilutions. All blots were imaged on a LI-COR Odyssey
instrument as directed by the manufacturer (LI-COR Biosciences,
Lincoln, NE, USA).
Bone marrow progenitor growth assay
Low-density cells from cooled human bone marrow collected
o24h before usage (purchased from Lonza Walkersville, Inc.,
Gaithersburg, MD, USA) were isolated by Ficoll density gradient
centrifugation (1.077gml
 1; Ficoll-Paque). Three different human
donor cells were used for these studies. Low-density marrow cells
were washed in RPMI 1640 medium with 10% FBS and plated in
T-75 flasks at 371C to remove adherent cells. After 1h incubation,
nonadherent cells were collected and 5 10
4cellsml
 1 were mixed
thoroughly with methocult (Stemcell Technologies, Vancouver,
Canada), recombinant growth factors, TKIs (ranging from 0.1nM
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sto 10mM), and media and dispensed in 12-well plates
(0.5mlwell
 1). Plates were incubated in a humidified low-oxygen
incubator (7.5% CO2,5 %O 2) for 10 days, and colonies of 450 cells
were counted microscopically. The growth factors used were
human GM-CSF (90ngml
 1), SCF (50ngml
 1), and Flt-3 ligand
(200ngml
 1) alone, and combinations of growth factors
GM-CSFþSCF, GM-CSFþSCFþFlt-3 ligand, and SCFþFlt-3
ligand. The numbers of progenitors that would grow in the
presence of SCF or Flt-3 alone were anticipated to be very low;
therefore, marrow-cell density plated was doubled to 1 10
5cellsml
 1
for these growth factors. Inhibitory concentration (IC)50 and IC90
values were calculated from the dose–response curves using
ExcelFit 4.0 (Microsoft, San Francisco, CA, USA) software tools
(four-parameter fits). Statistical analysis was performed with
GraphPad InStat (GraphPad, San Diego, CA, USA) software.
RESULTS
Kinase selectivity of various TKIs
Pazopanib, sorafenib, and sunitinib were tested in a panel of
242 kinases at 0.3 and 10mM (Supplementary Table 2). At 0.3mM,
29 kinases were inhibited 450% by pazopanib, whereas 49 and
26 kinases were inhibited by sunitinib and sorafenib, respectively.
At 10mM, a total of 94 kinases were inhibited 450% by pazopanib,
whereas 147 and 82 kinases were inhibited by sunitinib and
sorafenib, respectively. A set of 61 kinases that were inhibited by
450% at 0.3mM by at least one drug was selected for IC50
determination (Table 1). Pazopanib inhibited 32 kinases with an
IC50 o1mM, whereas sunitinib and sorafenib inhibited 54 and 25
kinases, respectively. As reported in the literature, the three TKIs
were potent inhibitors of VEGFR-1 (Flt-1), VEGFR-2 (KDR), and
VEGFR-3 (Flt-4), with very similar potency among compounds.
Pazopanib and sunitinib inhibited c-Kit activity with IC50 of 48 and
40nM, respectively, whereas sorafenib was much less active in this
assay (Table 1). Sunitinib was a more potent inhibitor of Flt-3
compared with pazopanib. Looking at the kinases selectively
targeted by these TKIs, sunitinib inhibited the activity of Mer,
CaMKIId, CaMKIIg, DRAK1, CHK2, PhKg2, and ARK5 kinases
quite potently (IC50o100nM), whereas pazopanib and sorafenib
had little to no activity against these kinases (IC50410000nM).
Pazopanib was more potent against MLK1 and TAO3 kinases
compared with the potency of sunitinib and sorafenib. Sorafenib
uniquely inhibited SAPK2a mutant and Mnk2 kinases with
submicromolar potency. Further, DDR2, TAO2, and c-RAF were
inhibited by pazopanib and sorafenib, but not by sunitinib. The
results indicate that all three inhibitors had activity against several
kinases in this panel, beyond those involved in tumour angiogen-
esis, which could modulate the cellular and antitumour activity of
these compounds.
For a more accurate determination of the potency of pazopanib,
sunitinib, and sorafenib against VEGFR-1, VEGFR-2, VEGFR-3,
PDGFR-a/b, Flt-3, and c-Kit kinases, affinity (Ki
app)v a l u e sw e r e
determined using either filter-binding or HTRF assays. All three
compounds showed comparable activity against VEGFR-2, VEGFR-3,
PDGFR-a,a n dP D G F R - b (Table 2). Pazopanib possessed the weakest
affinity for Flt-3 with a mean Ki value of 230nM, which is 25-fold
weaker compared with VEGFR-2. In contrast, sunitinib possessed
85-fold and 100-fold greater affinity for Flt-3 and c-Kit compared with
VEGFR-2 with Ki
app values of 0.6, 0.45, and 51nM, respectively.
Sorafenib showed the least selectivity among these tyrosine kinase
receptors with affinity values ranging from 2 to 22nM.
Cellular activity against various receptor tyrosine kinases
To compare the cellular activities of pazopanib, sunitinib, and
sorafenib, we evaluated their inhibitory effect against wild-type
VEGFR-2, c-Kit, PDGFR-b, and Flt-3 receptors in HUVEC, NCI-
H526, HFF, and RS4;11 cells, respectively. Serum-starved cells were
treated with inhibitors at various concentrations for 2h. Cells were
Table 1 IC50 values of pazopanib, sunitinib, and sorafenib against 61
kinases
IC50 (nM)
Kinase
a Pazopanib Sunitinib Sorafenib
Abl 624 556 1133
Abl(T315I) 406 222 957
ALK 5377 293 410000
ARK5 1108 85 410000
Aurora-A 64 508 1411
Axl 410000 259 6273
CaMKIIb 410000 519 410000
CaMKIIg 410000 20 410000
CaMKIId 410000 20 410000
CDK7/cyclinH/MAT 410000 133 410000
CHK2 410000 59 410000
CHK2(I157T) 410000 79 410000
CHK2(R145W) 410000 83 410000
CK1d 410000 206 410000
c-Kit(D816H) 45 24 95
c-Kit 48 40 1862
c-Kit(V560G) 1 o11 3
c-Kit(V654A) 1 1 170
c-RAF 92 410000 110
DDR2 474 410000 51
DRAK1 410000 54 410000
FGFR1 80 437 64
FGFR1(V561M) 4266 180 3908
FGFR2 350 852 825
FGFR2(N549H) 3 211 12
FGFR3 138 314 1019
Fgr 498 142 5260
Flt-3(D835Y) 186 3 1981
Flt-3 619 4 45
Fms 6 5 29
Lck 379 95 1495
MARK1 410000 475 410000
MELK 410000 145 410000
Mer 2096 12 2096
MLK1 21 987 410000
Mnk2 410000 410000 302
MST1 410000 221 410000
MuSK 5937 206 53
PDGFR-a(D842V) 296 161 61
PDGFR-a 73 143 933
PDGFR-a(V561D) o115
PDGFR-b 215 75 1129
PhKg2 410000 75 410000
PrKX 410000 410000 410000
PTK5 97 748 124
Pyk2 1664 480 410000
Ret 232 37 2
Rse 410000 251 410000
Rsk2 410000 380 410000
Rsk3 410000 215 6166
Rsk4 410000 238 410000
SAPK2a(T106M) 410000 410000 201
SAPK2b 5656 410000 4 10000
TAK1 410000 150 1226
TAO2 382 410000 67
TAO3 181 410000 410000
TrkA 937 23 218
TrkB 4282 158 832
VEGFR-1 7 21 9
VEGFR-2 15 34 28
VEGFR-3 2 3 7
Yes 667 45 410000
Abbreviations: IC¼inhibitory concentration; PDGFR¼platelet-derived growth factor
receptor; VEGFR¼vascular endothelial growth factor receptor.
aAll human kinases.
Myelosuppression and kinase selectivity of TKIs
R Kumar et al
1719
British Journal of Cancer (2009) 101(10), 1717–1723 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sthen stimulated with respective ligands as described in Materials
and Methods. Whole-cell lysates were collected after 10min of
ligand stimulation, and the total receptor was immunoprecipitated
using antireceptor antibodies. The ligand-induced receptor activa-
tion was detected by anti-pTyr antibody following western blot
analysis. All three compounds inhibited the ligand-induced
activation of VEGFR-2, c-Kit, PDGFR-b, and Flt-3 receptors
(p-Tyr) in a dose-dependent manner, whereas total receptor levels
remained constant (Figure 1). The three compounds exhibited
similar potency in suppressing activation of VEGFR-2 and PDGFR-
b (Table 3). However, sunitinib showed 10-fold greater potency
than pazopanib and 100-fold greater potency than sorafenib
against c-Kit activation (Figure 1; Table 3). Sunitinib and sorafenib
both potently inhibited wild-type Flt-3 receptor activation with
IC50 of 1nM, whereas pazopanib was 1000-fold less active against
Flt-3 with IC50X1mM.
Effect on human bone marrow progenitor cell growth
As haematopoietic progenitor cell proliferation and differentiation
are regulated by various growth factors, including SCF and Flt-3
ligand, the human bone marrow progenitor cell growth was
evaluated in the presence of various ligands using colony
formation assay. The number of colony forming units (CFUs)
formed was growth factor dependent. Use of GM-CSF resulted in
an average CFU count of 56 in three studies (Figure 2A). The
addition of SCF to GM-CSF increased the number of CFUs to an
average of 98, consistent with the known synergistic activity of SCF
on CFU growth. Addition of Flt-3 ligand to GM-CSF and SCF
resulted in further augmented CFU formation. The combination of
SCF with Flt-3 ligand resulted in the formation of 51 CFUs. The
number of CFUs formed in the presence of SCF or Flt-3 ligand
alone was determined in cultures plated with double the number of
enriched marrow cells. The presence of SCF alone resulted in very
few CFUs, with only six CFUs formed in one study; Flt-3 alone
resulted in an average of 15 CFU in three studies. Of note, less than
Table 2 Activity of pazopanib, sunitinib, and sorafenib against purified
kinases
Ki
app (nM)
Enzyme Pazopanib Sunitinib Sorafenib
VEGFR-1 15 229 10
VEGFR-2 8 51 4
VEGFR-3 10 30 6
PDGFR-a 30 28 2
PDGFR-b 14 7 5
c-Kit 2.4 0.45 15
Flt-3 230 0.6 22
Abbreviations: Ki
app¼apparent inhibition constant; PDGFR¼platelet-derived growth
factor receptor; VEGFR¼vascular endothelial growth factor receptor.
Compound [nM] 10000 1000 100   10     1     0.1   0.01   0  10000 1000 100   10     1     0.1  0.01    0    10000 1000 100   10      1     0.1   0.01   0
Pazopanib Sunitinib Sorafenib
FLT-3
PDGFR-
c-Kit
Total
pTyr
VEGFR-2
Total
pTyr
Total
pTyr
Total
pTyr
Figure 1 Inhibition of receptor autophosphorylation by various tyrosine kinase inhibitors. To compare the activities of pazopanib, sunitinib, and sorafenib,
we evaluated their inhibitory effects against wild-type VEGFR-2, c-Kit, PDGFR-b, and Flt-3 receptors in HUVEC (for VEGFR-2), NCI-H526 (c-Kit), HFF
(PDGFR-b), and RS4;11 (Flt-3). Cells were serum-starved overnight and then treated with DMSO or different concentrations of pazopanib, sunitinib, or
sorafenib for 2h. Cells were then stimulated with respective ligands as described in the cellular autophosphorylation section under Materials and Methods.
Total receptor was immunoprecipitated using antireceptor antibodies and phosphorylation was detected using anti-pTyr antibody following western blot
analysis.
Table 3 Cellular IC50 for inhibition of ligand-induced receptor auto-
phosphorylation
IC50 (nM)
Receptors Cells Pazopanib Sunitinib Sorafenib
VEGFR-2 HUVEC 8 5 10
PDGFR-b HFF 3 2 7
c-Kit NCI-H526 2.6 0.3 29
Flt-3 RS4;11 X1000 1 1
Abbreviations: HUVEC¼human umbilical vein endothelial cells; IC¼inhibitory
concentration; PDGFR¼platelet-derived growth factor receptor; VEGFR¼vascular
endothelial growth factor receptor.
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sone CFU formed in cultures without any growth factor addition;
therefore, no background correction was needed in these studies.
The inhibitory properties of pazopanib, sorafenib, and sunitinib
were dependent on the growth factor(s)/ligand(s) used to initiate
colony formation (Figure 2B and C). Pazopanib and sorafenib had
modest effect on GM-CSF–driven CFU-GM formation with an IC50
of 1 and 1.7mM, respectively. Growth factor additions, which
contained SCF, resulted in a shift in potency of pazopanib by 2- to
6-fold to the nM range, whereas CFU inhibition by Flt-3 ligand
alone was similar to CFU inhibition driven by GM-CSF. Addition
of SCF or Flt-3 ligand resulted in modest shifts in potency of
sorafenib to the nM range, whereas CFU inhibition by Flt-3 ligand
alone was similar to CFU inhibition driven by GM-CSF. Sunitinib
was more potent than the other two compounds in inhibiting CFU-
GM formation induced by GM-CSF (IC50¼32.7nM). Addition of
SCF or Flt-3 ligand with GM-CSF resulted in significant shifts in
potency of sunitinib to the low nM range.
The drug concentration that inhibited the CFU-GM by 90%
(IC90) was more predictive of clinical measurement of the
myelosuppressive dose than the often published IC50 values
(Pessina et al, 2001). Therefore, we calculated both IC50 and IC90
values for pazopanib, sunitinib, and sorafenib in bone marrow
progenitor growth assays in the presence of various ligands. The
IC90 values for pazopanib and sorafenib inhibition of CFU were
often extrapolated because CFU formation occurred at the highest
concentration tested (10mM). Compared with GM-CSF, the shift in
IC90 values for pazopanib after the addition of SCF was 15-fold for
GM-CSFþSCF and six-fold for SCFþFlt-3 ligand. For sorafenib,
none of the IC90 values were statistically significantly shifted
compared with GM-CSF; however, the average IC90 values were
30- and 11-fold more potent for the Flt-3 ligand alone and Flt-3
ligand þ SCF groups. Similar to IC50 results, sunitinib showed
9- to 28-fold shifts in CFU IC90 values with SCF and/or Flt-3
ligands compared with GM-CSF alone. The results suggest that
sunitinib is a potent inhibitor of CFUs driven by GM-CSF and Flt-3
ligand, and that sunitinib’s inhibitory activity is greatly enhanced
with the activation of c-Kit receptor signalling.
DISCUSSION
Off-target activity of drugs often results in unwanted and generally
harmful effects, and a better understanding of the target profile of
drugs can help design agents that may avoid/minimize activities
against undesired targets (Liebler and Guengerich, 2005; Campillos
et al, 2008). Large-scale molecular profiling of agents against a
panel of related proteins is often the first step in evaluating
selectivity. A number of kinase inhibitors have shown promising
clinical activity and several are now approved (Baselga, 2006;
Sebolt-Leopold and English, 2006; Zhang et al, 2009). All of these
agents have activity against other kinases to various degrees
(Karaman et al, 2008), which may be associated with their adverse-
event profiles. Comparing three TKIs targeting VEGF signalling,
against a large panel of kinases, we observed differences in their
inhibitory potential against various kinases, although they have
relatively similar potency against VEGFR-2. Sunitinib had the
broadest kinase activity among the three TKIs, with 20% of the
kinases (49 of 242) inhibited by 450% at 0.3mM, whereas
pazopanib and sorafenib inhibited 12% and 11% of the tested
kinases, respectively. Although there is overlap in the specific
kinases inhibited by pazopanib and sorafenib, there are also clear
distinction for some of the kinases, for example, sorafenib is a
more potent inhibitor of DDR2, MuSK, MnK2, Ret, and so on,
whereas pazopanib is more potent against Aurora-A and MLK1.
Our results are generally consistent with published selectivity
results for the three compounds using binding assays against a
panel of 290 kinases, wherein sunitinib bound to five times more
kinases than pazopanib, with a Kdo100nM (Karaman et al, 2008).
The selectivity was more evident for serine/threonine kinases,
where sunitinib interacted with 36 times more kinases than
pazopanib. For tyrosine kinases, the difference was only 1.8-fold.
On the other hand, the selectivity ratio of sorafenib was only
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Figure 2 Effect of tyrosine kinase inhibitors (TKIs) on ligand-stimulated
progenitor cell growth. (A) Human bone marrow progenitor cells were
stimulated with GM-CSF (90ngml
 1), SCF (50ngml
 1), Flt-3 ligand
(200ngml
 1), and their various combinations for colony stimulating unit
(CFU) formation. Less than one CFU formed in cultures without any
growth factor addition, thus no background correction was needed. (B and
C) Bone marrow progenitor cells were treated with pazopanib, sunitinib,
and sorafenib at concentrations ranging from 0.1nM to 10mM in the
presence of various ligands. Inhibitory potentials, IC50 (B) and IC90 (C), of
TKIs were calculated for ligand-induced CFU formation. Data represent
meanþs.d. from three human bone marrow preparations. *Significantly
different than GM-CSF alone; Po0.01 by Dunnett’s Multiple Comparison
test.
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same data set.
Among the tyrosine kinases, related to VEGFR-2, there were
subtle differences in the potencies of the three TKIs against c-Kit
and Flt-3, with sunitinib having the highest affinity for both of
these targets. Sorafenib had modest activity against both c-Kit and
Flt-3 kinases; however, pazopanib was much less active against Flt-
3, although it inhibited c-Kit kinase (Table 2). The selectivity
against in vitro kinases translated into the ability of TKIs to inhibit
ligand-induced receptor autophosphorylation, where pazopanib
was a very weak inhibitor of Flt-3 activation (Figure 1). The
differences in the activity of these TKIs against such closely related
receptor tyrosine kinases clearly demonstrate the need to broadly
profile drugs to understand their true selectivity and potential
off-targets.
As GM-CSF, Flt-3, and c-Kit are involved in the development of
various haematopoietic lineage cells, we evaluated the reported
adverse-effect profiles of these TKIs in clinical trials. All three TKIs
have been shown to cause myelosuppression, although the
frequency and severity vary (Motzer et al, 2006, 2007; Escudier
et al, 2007; Bhojani et al, 2008; Sternberg et al, 2009). Sunitinib
appeared to have higher rates of lymphopenia and neutropenia
compared with sorafenib and pazopanib, although most were
grade 1/2 events and not dose limiting. It is important to highlight
that although all three agents were tested in patients with renal cell
carcinoma, no comparative study was reported and thus caution
should be used in comparing the results from different studies.
Human bone marrow progenitor cell growth using GM-CSF
(CFU-GM) has been used as a predictive assay to identify
compounds with myelosuppression capacity (Pessina et al, 2001,
2005). The interaction of GM-CSF with its receptor on human bone
marrow progenitors, including various kinases, signals a series of
biochemical events with resultant growth and differentiation. The
addition of synergistic growth factors such as Flt-3 ligand and SCF
are known to increase the number of responding progenitors that
grow in the presence of GM-CSF. The increased number and
continued discovery of more targeted agents that specifically
inhibit key biochemical components of the receptor signalling
pathways may require modification of the standard CFU-GM assay
to better predict the inhibitory nature of these TKIs.
Different TKIs inhibited the bone marrow colony formation with
different potency, with sunitinib having the highest activity
(Figure 2). Addition of SCF and/or Flt-3 ligand with GM-CSF
resulted in increased colony formation as expected. Consistent
with the strong inhibition of c-Kit and Flt-3 kinases by sunitinib, it
showed enhanced inhibitory activity in the CFU assay done in the
presence of SCF and Flt-3 ligand. The changes in the IC50 and IC90
values with the addition of SCF and Flt-3 ligand were less
pronounced for pazopanib and sorafenib, and were in general
agreement with their activity against these kinases. Sunitinib
induced inhibition of bone marrow progenitors was broader than
both pazopanib and sorafenib. The mechanism for this broad-
spectrum inhibition of progenitors in vitro in not completely
understood, but is likely due to the potent inhibition of both c-KIT
and flt-3 kinases. Both c-kit and flt-3 are important kinases in early
stem and progenitor cell development; therefore, inhibition of both
of these kinases may result in the observed sensitivity of
haematopoietic progenitors in vitro especially with the addition
of SCF and FLT-3 ligand to further augment progenitor growth. As
sunitinib inhibits a larger number of kinases than pazopanib and
sorafenib, the contribution from other kinases cannot be ruled out.
The data presented in this report clearly indicate that the testing of
TKIs (such as pazopanib, sorafenib, and sunitinib) in the standard
GM-CSF–induced CFU-GM assay, although useful, does not
represent the inhibitory potential of these targeted kinase
inhibitors in human bone marrow assays. For a better evaluation
of the myelosuppressive potential of TKIs, the CFU assay should be
done in the presence of various ligands.
In summary, activity against other targets can explain the
differences in clinical effects for various kinase inhibitors, and a
better understanding of the contributions of various kinases to the
different adverse effects may help in designing optimally targeted
inhibitors. The differences in the activity against c-Kit and Flt-3
kinases among sunitinib, sorafenib, and pazopanib provide a likely
explanation for the observed difference in clinical myelosuppres-
sion with these antiangiogenic TKIs.
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